Home 5 Articles 5 Agency Okays COVID-19 Blood Spot Self-Collection & Molecular Test Pooling

Agency Okays COVID-19 Blood Spot Self-Collection & Molecular Test Pooling

by | Jun 14, 2021 | Articles, FDA-lir, Laboratory Industry Report

Pandemic pressures continue to produce unprecedented action from the FDA. The current imperative is to clear assays and collection kits for rapid and easy screening, including products that can be used in home settings. A new barrier was crossed on April 6 when the agency granted Emergency Use Authorization (EUA) for a SARS-CoV-2 antibody detection […]

Pandemic pressures continue to produce unprecedented action from the FDA. The current imperative is to clear assays and collection kits for rapid and easy screening, including products that can be used in home settings. A new barrier was crossed on April 6 when the agency granted Emergency Use Authorization (EUA) for a SARS-CoV-2 antibody detection test used in dried blood spot samples collected at home.

The Symbiotica System

The groundbreaking EUA went to Symbiotica’s COVID-19 Self-Collected Antibody Test System, a prescription-only test designed to detect immunoglobulin G against SARS-CoV-2 in dried blood spots obtained via fingerstick. The kit includes lancets that individuals can use to collect the blood samples themselves and mail to Symbiotica’s California lab for analysis.

“The authorization of the first prescription use, home collection antibody test will play an important role in helping health care professionals identify individuals who have developed an adaptive immune response from a recent or prior COVID-19 infection,” noted Jeff Shuren, director of the FDA’s Center for Devices and Radiological Health, in a statement.

Molecular Test Pooling

Two weeks after clearing the Symbiotica system, the agency amended its guidelines to facilitate authorization for pooling by allowing molecular COVID-19 tests with EUA to be used with pooled samples performed to screen the asymptomatic as part of a “serial testing program,” such as in a school or workplace setting. In other words, specific clearance for the use isn’t required as long as the test developer self-certifies that it has validated the test for pooling and submits its validation data and pooling procedures.

Here are the other key new FDA EUAs and clearances announced in May:

New FDA Emergency Use Authorizations (EUAs) & Approvals

Manufacturer(s)Product
DiaSorinEUA for Liaison SARS-CoV-2 TrimericS IgG chemiluminescent immunoassay
SalofaEUA for Sienna-Clarity COVID-19 Antigen Rapid Test Cassette
Harvard UniversityEUA for point of care immunoassay Quaeris SARS-CoV-2 Assay
NowDiagnosticsEUA for AdexusDx COVID-19 Test lateral flow immunoassay
Janssen PharmaceuticalAccelerated approval for EGFR-MET bispecific antibody amivantamab (Rybrevant) to treat EGFR exon 20-mutated NSCLC
Phosphorus DiagnosticsEUA for direct-to-consumer version of saliva-based SARS-CoV-2 assay and use of at-home sample collection kit with test
LabCorpEUA for Pixel by Labcorp COVID-19 PCR Test Home Collection Kit expanded to allow for use by children and adolescents at least 2 years of age
MolzymBreakthrough Device Designation for molecular diagnostic test system for diagnosis of bloodstream infections
Zeus ScientificEUA for ELISA SARS-CoV-2 Total Antibody Test System
QiagenEUA for QiaReach Anti-SARS-CoV-2 Total Test to identify if person has SARS-CoV-2 antibodies from a prior infection
InBios InternationalEUA for point-of-care SCoV-2 Ag Detect Rapid Test for SARS-CoV-2 antigens
ViomeBreakthrough Device Designation for mRNA analysis and AI saliva-based oral and throat cancer detection technology
Quadrant BiosciencesBreakthrough Device Designation for Clarifi ASD assay to detect markers of autism spectrum disorder
RocheClearance for Ventana MMR RxDx immunohistochemistry panel as companion diagnostic to select endometrial cancer patients for treatment with dostarlimab
PathogenDxEUA for molecular DetectX-Rv SARS-CoV02test
Southern California Permanente Medical GroupEUA for SCPMG’s Kaiser Permanente High Throughput SARS-CoV-2 Assay
Inova DiagnosticsEUA for Quanta Flash SARS-CoV-2 IgG chemiluminescent immunoassay
Immunodiagnostic Systems510(k) clearance for IDS Cortisol assay to detect cortisol in human serum and plasma on firm’s IDS system
Retractable Technologies510(k) clearance for EasyPoint Blood Collection Plus blood collection tube holder
Immunalysis510(k) clearance for Sefria PCP Oral Fluid Enzyme Immunoassay

New CE Marks & Global Certifications

Notable European CE certifications announced during the period:

NEW CE MARKINGS IN EUROPE

Manufacturer(s)Product(s)
Lucid DiagnosticsEsoCheck Esophageal Cell Collection Device with Collect+Protect technology
Advanced Biological LaboratoriesDeepChek Assay Whole Genome SARS-CoV-2 Genotyping V1
Advanced Biological LaboratoriesUltraGene SARS-CoV-2 Triplex Assay
BGI GenomicsDNA Methylation Detection Kit for Human SDC2, ADHFE1, and PPP2R5C Genes in colorectal cancer screening
TassoTasso-M20 self-sampling blood collection device
GenomtecSaliva-based SARS-Cov-2 EvaGreen Direct-RT-LAMP Kit
BforCureChronos Dx portable qPCR thermocycler for use in SARS-CoV-2 testing
Becton DickinsonHuman papillomavirus assay with at-home self-collection indication
Bio Molecular SystemsPortable MIC qPCR thermo cycler
BioEcho Life SciencesEchoLution Viral RNA/DNA Swab Kit
Ortho Clinical DiagnosticsVitros Anti-SARS-CoV-2 IgG Quantitative Antibody test
Purigen BiosystemsIonic Purification System for nucleic acid isolation
BioMérieuxVitek MS Prime, its new MALDI-TOF microbiology system
BioMérieuxVidas SARS-CoV-2 IgG II test
Siemens HealthineersClinitest Rapid COVID-19 Antigen Self-Test for unsupervised self-testing, including testing at home on the asymptomatic
Bio-Rad LaboratoriesReliance SARS-CoV-2 RT-PCR Kit
SpeeDxPlexPCR SARS-CoV-2 test

Other international clearances announced during the period:

Manufacturer(s)Country(ies)Product(s)
Bio Molecular SystemsAustraliaPortable MIC qPCR thermo cycler
Lucira HealthCanadaLucira Check It COVID-19 test kit

Subscribe to view Essential

Start a Free Trial for immediate access to this article